January 20, 2017 1:56 AM ET

Pharmaceuticals

Company Overview of Mega Lifesciences Public Company Limited

Company Overview

Mega Lifesciences Public Company Limited, together with its subsidiaries, develops, manufactures, markets, and sells health food supplements, prescription pharmaceutical products, over-the-counter (OTC) products, herbal products, vitamins, and fast moving consumer goods under the Mega We Care brand. It operates through Brands, Distribution, and Original Equipment Manufacture segments. The company provides various complementary medicines for bone and joint, children, diabetic, herbal, heart, liver and digestive, skin, slimming, sports supplements, and well-being care products, as well as men’s and women’s care products; gastrointestinal and pain care OTC medicines; and prescription medicines ...

Ample Tower

9th -10th Floor

No. 120, Moo 11, Bangna-Trad Road

Bangna

Bangkok,  10260

Thailand

Founded in 1982

Phone:

66 2 769 4222

Fax:

66 2 769 4244

Key Executives for Mega Lifesciences Public Company Limited

Mega Lifesciences Public Company Limited does not have any Key Executives recorded.

Mega Lifesciences Public Company Limited Key Developments

Mega Lifesciences Public Company Limited Announces Unaudited Consolidated and Parent Earnings Results for the Third Quarter and Nine Months Ended September 30, 2016

Mega Lifesciences Public Company Limited announced unaudited consolidated and parent earnings results for the third quarter and nine months ended September 30, 2016. For the quarter, on the consolidated basis, the company reported revenue from sales of goods and rendering services of THB 2,175.6 million against THB 1,885.5 million a year ago. EBITDA was THB 237.3 million against THB 212.8 million a year ago. Profit before tax was THB 193.7 million against THB 175.3 million a year ago. Net profit was THB 167.9 million against THB 152.5 million a year ago. Increase in net profits was mainly a result of increase in revenue and stable segmental gross margins. Adjusted net profit was THB 176.1 million against THB 152.5 million a year ago. Earnings before interest & tax (EBIT) were THB 200.5 million against THB 178.7 million a year ago. Basic and diluted earnings per share were THB 0.19 against THB 0.18 a year ago. Net profit attributable to the company was THB 167,892,000 against THB 152,493,000 a year ago. For the nine months, on consolidated basis, the company reported revenue from sales of goods and rendering services of THB 6,214.7 million against THB 5,662.7 million a year ago. EBITDA was THB 714.9 million against THB 618.2 million a year ago. Profit before tax was THB 588.8 million against THB 503.5 million a year ago. Net profit was THB 499.9 million against THB 424.5 million a year ago. Adjusted net profit was THB 512.7 million against THB 424.5 million a year ago. Earnings before interest & tax (EBIT) were THB 603.5 million against THB 512.8 million a year ago. Basic and diluted earnings per share were THB 0.58 against THB 0.49 a year ago. Net profits were impacted by net forex loss of THB 81.8 million mainly driven by devaluation of Nigerian currency amounting to THB 59.8 million. Operating activities generated THB 904.9 million of cash compared to THB 340.3 million a year ago. Increase in operating cash was mainly a result of increase in profits and improvement in overall working capital. Net profit attributable to the company was THB 499,940,000 against THB 424,472,000 a year ago. Purchase of property, plant and equipment was THB 247,479,000 against THB 129,234,000 a year ago. Purchase of intangible assets was THB 13,178,000 against THB 11,798,000 a year ago. For the quarter, on the parent basis, the company reported revenue from sales of goods and rendering services of THB 702,931,000 against THB 659,269,000 a year ago. Profit before income tax expense was THB 166,369,000 against THB 199,261,000 a year ago. Basic and diluted earnings per share were THB 0.18 against THB 0.21 a year ago. Net profit attributable to the company was THB 156,325,000 against THB 183,775,000 a year ago. For the nine months, on the parent basis, the company reported revenue from sales of goods and rendering services of THB 2,035,934,000 against THB 1,816,529,000 a year ago. Profit before income tax expense was THB 434,713,000 against THB 433,076,000 a year ago. Basic and diluted earnings per share were THB 0.47 against THB 0.47 a year ago. Net profit attributable to the company was THB 403,414,000 against THB 406,579,000 a year ago. Operating activities generated THB 665,110,000 of cash compared to THB 437,355,000 a year ago. Purchase of property, plant and equipment was THB 206,352,000 against THB 41,544,000 a year ago. Purchase of intangible assets was THB 3,178,000 against THB 4,571,000 a year ago.

Mega Lifesciences Public Company Limited Presents at Opportunity Day 3Q 2016, Dec-06-2016 08:40 AM

Mega Lifesciences Public Company Limited Presents at Opportunity Day 3Q 2016, Dec-06-2016 08:40 AM. Venue: The Stock Exchange of Thailand, Meeting Room 603, Bangkok, Thailand.

Mega Lifesciences Public Company Limited Establishment Joint Venture with Malee Group Public Company Limited

Mega Lifesciences Public Company Limited announced establishment of a joint venture with Malee Group Public Company Limited. Mega Lifesciences Public Company Limited investment ration 51% and Malee Group Public Company Limited investment ration 49% to developnew businsess for health related natural food and beverage for Thai and international market with the initial investment capital of THB 10,000,000.

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Mega Lifesciences Public Company Limited, please visit www.megawecare.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.